Last reviewed · How we verify
NCT05401721
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
trial testing Serum copeptin in Spontaneous Bacterial Peritonitis in 89 participants. Completed in 1 December 2021.
1 December 2021
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 89 |
| Start date | 1 May 2021 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Serum copeptin
Conditions studied
- Spontaneous Bacterial Peritonitis — all drugs for Spontaneous Bacterial Peritonitis →
Sponsor
Sohag University
Who can join
Adults 18 to 80, any sex, with Spontaneous Bacterial Peritonitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. To the best of our knowledge, few studies have addressed the association between copeptin and sepsis in cirrhotic patients, however, they were performed on different types of infections. Therefore, we will conduct this study with a focus on it is possible role in patients with SBP.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Serum copeptin is associated with major complications of liver cirrhosis and spontaneous bacterial peritonitis.
Abudeif A, Hashim MS, Ahmed NM, Ahmed AO. · · 2023 · cited 3× · PMID 37064833 · DOI 10.5114/ceh.2023.125970
Verify or expand the search:
- PubMed search for NCT05401721
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Serum copeptin
Trials testing the same drug.
- NCT07154134 — Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome · recruiting
Other recruiting trials for Spontaneous Bacterial Peritonitis
Currently open trials in the same condition.
- NCT06026267 — Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontan · NA · recruiting
- NCT04168099 — Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis · Phase 3 · recruiting
- NCT04161768 — Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis · Phase 3 · recruiting
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05401721 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 2 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05401721.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing